| Id |
Subject |
Object |
Predicate |
Lexical cue |
| T245 |
0-204 |
Sentence |
denotes |
In public health emergencies, such as the COVID-19 pandemic, regulators are expected to act quickly to support accelerated vaccine development through the introduction of increased regulatory flexibility. |
| T246 |
205-455 |
Sentence |
denotes |
To guide the accelerated vaccine development and approval for COVID-19, the Chinese regulatory agencies and the National Medical Products Administration (NMPA) have issued seven guidelines since March 2020 to provide a roadmap and requirements [116]. |
| T247 |
456-605 |
Sentence |
denotes |
Moreover, the Chinese NMPA has formulated a special scheme to synchronize the protocol reviewing process with the research and development processes. |
| T248 |
606-792 |
Sentence |
denotes |
Consequently, completion of the vaccine development and the review may take place simultaneously so that the vaccine development can proceed to clinical application without major delays. |
| T249 |
793-956 |
Sentence |
denotes |
For example, the NMPA completed the review process of the Sinopharm COVID-19 vaccine application within just 24 h, although such a review would normally take 60 d. |
| T250 |
957-1191 |
Sentence |
denotes |
Thus far, there have been ten Chinese COVID-19 vaccine candidates in the pipeline of clinical trials [114], [117], [118], [119], [120], [121], [122], [123], in four of which international phase III clinical trials have been initiated. |
| T251 |
1192-1291 |
Sentence |
denotes |
Furthermore, more than 21 preclinical projects may have the potential to move into clinical trials. |
